--- title: 'Life Sciences Daily Summary: What Happened on October 28, 2026' headline: Vanda reports Phase 3 results for tradipitant and GLP-1-related vomiting description: Lilly says retatrutide beat Ozempic on blood sugar and weight measures. Arrowhead won UK authorization for Redemplo, with NHS funding recommended for eligible patients. url: https://thebench.bio/news/summaries/2026-10-28 topic: all date: '2026-10-28' covers: - '2026-10-28' date_published: '2026-10-28T12:04:22Z' date_modified: '2026-10-28T12:04:22Z' tags: - Clinical - Regulatory - Research sources: 3 publisher: TheBench.Bio --- # Life Sciences Daily Summary: What Happened on October 28, 2026 **Vanda reports Phase 3 results for tradipitant and GLP-1-related vomiting** Lilly says retatrutide beat Ozempic on blood sugar and weight measures. Arrowhead won UK authorization for Redemplo, with NHS funding recommended for eligible patients. ## Today in brief Vanda’s tradipitant reduced vomiting in a Phase 3 trial that gave participants semaglutide without the usual dose escalation. [1] Lilly said its investigational drug retatrutide beat Ozempic on blood sugar and weight measures in a diabetes study. [2] Arrowhead received UK authorization for Redemplo, and NICE recommended NHS funding in England and Wales for eligible patients. [3] ## Tradipitant reduced vomiting after a semaglutide dose in a Phase 3 trial Vomiting occurred in 43.0% of participants receiving Vanda Pharmaceuticals’ tradipitant and 58.5% receiving placebo, a site-adjusted relative reduction of 27%. [1] The randomized, placebo-controlled trial gave participants one 1 mg dose of semaglutide without the usual dose escalation, under conditions expected to provoke vomiting. [1] Vomiting with severe nausea affected 33.1% of the tradipitant group and 50.6% of the placebo group, an adjusted relative decrease of 35%. [1] Exploratory analyses found fewer cases of frequent vomiting, defined as more than two episodes on multiple days, and 81% fewer episodes among participants with more than ten. [1] Vanda said it plans to discuss the combined Phase 2 and Phase 3 findings with regulators and submit a supplemental new drug application to the FDA for this use. [1] ## Retatrutide reduced blood sugar and weight more than Ozempic in Lilly’s study At the highest dose, retatrutide was associated with a 2.2 percentage-point drop in A1c after 80 weeks, compared with a 1.8-point drop for Ozempic. [2] Participants on the highest retatrutide dose lost 20.9% of their weight, versus 9.4% on Ozempic, in analyses of participants who stayed on treatment. [2] Lilly described the head-to-head results as showing better blood sugar and weight reduction with retatrutide, which remains investigational. [2] ## UK authorizes Redemplo, with NHS funding recommended for eligible patients The UK authorized Arrowhead Pharmaceuticals’ Redemplo, or plozasiran, as an addition to diet to lower triglycerides in adults with familial chylomicronemia syndrome. [3] NICE recommended NHS funding in England and Wales for adults with genetically confirmed disease whose condition is not adequately controlled by diet and standard triglyceride-lowering treatments, under a commercial arrangement. [3] The authorization applies across the UK, while the NICE recommendation guides NHS care in England and Wales. Northern Ireland has a separate validation process, and Scotland requires an independent reimbursement appraisal. [3] The authorization drew on PALISADE, a Phase 3 placebo-controlled study of 75 adults that measured the change in fasting triglycerides at month ten. [3] ## The day in numbers - **27%**: Site-adjusted relative reduction in vomiting with tradipitant versus placebo. [1] - **20.9% vs. 9.4%**: Weight loss with the highest retatrutide dose and Ozempic, respectively, among participants who remained on treatment. [2] - **75**: Adults enrolled in the PALISADE study supporting Redemplo’s UK authorization. [3] ## Sources 1. [Vanda reports Phase III tradipitant trial data in GLP-1-associated vomiting](), Clinical Trials Arena, 2026-10-28 2. [STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study](), STAT Biotech, 2026-10-28 3. [Arrowhead gains UK marketing authorisation for Redemplo](), Pharmaceutical Technology, 2026-10-28 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: